Ana E. P.
- Country
- Spain
- Department
- Digestive
Research Overview
- A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis
- Efficacy and Safety of Obefazimod (ABX464) in Adults with Moderately to Severely Active Ulcerative Colitis: A Randomized Placebo‑Controlled Phase III Study
- Phase 3b, Randomized, Open‑Label, Active‑Controlled Trial Comparing Guselkumab Versus Risankizumab for Efficacy and Safety in Moderately to Severely Active Crohn’s Disease
Data & Insights
Has run more than one trial at 313 of 524 partner sites.
Specializations
Inflammatory Bowel Disease Research
This investigator specializes in advanced therapeutic approaches for inflammatory bowel diseases, with particular emphasis on both adult and pediatric populations.
- Crohn's Disease management and treatment
- Ulcerative Colitis therapeutic interventions
- Pediatric IBD treatment protocols
The research encompasses novel therapeutic agents and their applications in treating various manifestations of IBD.
Specialized Treatment Areas
The investigator focuses on treating complex presentations of inflammatory bowel conditions, including:
- Fistulizing perianal Crohn's disease
- Moderately to severely active disease states
- Treatment-resistant conditions
Their work includes evaluation of innovative biological therapies and targeted treatment approaches.
Therapeutic Innovation
The investigator explores cutting-edge treatments including:
- Novel biological agents development
- Long-term therapeutic strategies
- Pharmacokinetic studies in diverse patient populations
Their research encompasses both established and experimental therapeutic approaches for inflammatory bowel conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.